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 Abstract 
 Aims: The aim is to study the prevalence and possible relationship of apathy and leukoarai-
osis in cases of cognitive impairment of varying severity in Spain.  Methods: We conducted a 
cross-sectional, descriptive, multicenter study involving 109 patients with Alzheimer’s disease 
(AD) and 59 with mild cognitive impairment (MCI).  Results: The older group with AD had a 
higher prevalence of leukoaraiosis and apathy, with significant differences compared to the 
MCI group.  Conclusions: To our knowledge, this is the first multicenter study in our country 
that jointly analyzes the presence of apathy and leukoaraiosis in the institutionalized elderly 
with varying degrees of cognitive impairment according to the most recent criteria for detect-
ing apathy in dementia.  © 2014 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is the leading cause of dementia and is characterized by a 
progressive decline of cognitive function, which typically begins with memory impairment. 
Ferri et al.  [1] , in a Delphi study published in 2005, estimated that 24 million individuals have 
dementia, a figure that is predicted to double every 20 years until 2040 with a forecast of 81 
million patients in 2005. The last global report on AD published in 2012  [2] , following the 
estimates in the 2010 report  [3] , indicates that in 2030 there will be 66 million AD patients, 
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increasing to 115 million in 2050. The WHO data published in 2012 are even more alarming: 
a new case of AD is diagnosed every 4 s, with an estimated 682 million subjects suffering from 
dementia over the next 40 years unless an effective treatment or cure  [4] is found.
 The latest recommendations by the National Institute of Neurological Disorders and 
Communication and the Association of Related Alzheimer’s Disease in the United States 
(NINCDS-ADRDA) for the diagnosis of AD disorders  [5] and mild cognitive impairment (MCI) 
 [6] emphasize the importance of early detection, broadening diagnostic criteria to items such 
as biomarkers, neuroimaging of specific injuries, and a battery of psychological tests that is 
as complete as possible.
 Given the fact that MCI is a taxonomy that has become particularly relevant in recent 
years and based on the ever-growing literature on the subject that speaks of a high percentage 
of patients progressing to AD  [7, 8] , it is interesting to look for factors that may influence the 
evolution towards dementia in order to establish early screening and therapeutic measures. 
This is not only due to the repercussions of detecting MCI cases but also to the fact that, 
regarding diagnosis, there still do not exist diagnostic instruments that are based on the 
recent recommendations  [9, 10] .
 The presence of leukoaraiosis and the high prevalence of apathy have been addressed 
together in very few studies. This is why the two concepts that have gained prominence in recent 
years in relation to dementia will be addressed in this study. Our research is a pioneer study in 
our country as it addresses the prevalence of both processes in patients with MCI and AD 
according to recent consensus criteria that have been developed for the diagnosis of apathy, 
MCI, and AD. The term radiological leukoaraiosis is a nonspecific term found in computed 
tomography (CT) or magnetic resonance imaging (MRI) and denotes patches of hypo- or hyper-
intensity mainly in periventricular white matter and subcortical regions  [11] . These ischemic 
lesions originate from an affectation of small vascular vessels and, hence, are also known as 
nonspecific white matter changes and small vessel ischemia. These lesions are frequently 
detected in elderly patients, with a higher prevalence in individuals with cerebrovascular 
disease, hypertension or diabetes, which are known to act as risk factors in the elderly  [12–14] . 
Clinical manifestations may be absent; however, they are sometimes present with different 
cognitive affectations  [15] . The prevalence is unclear because there is no consensus in the liter-
ature reviewed; the ranges found vary from 5 to 95%  [16] . Apathy and leukoaraiosis are mostly 
detected in asymptomatic individuals over 60 and in subjects with cognitive impairment, partic-
ularly in cases of cerebrovascular disease or vascular risk factors for ischemic stroke. Among 
patients with suspected cognitive impairment of vascular origin, leukoaraiosis is detected by CT 
between 41 and 100%  [15, 17] and between 64 and 100% by MRI. AD ranges from 19 to 78% 
in studies of CT and from 7.5 to 100% in studies of brain MRI, but usually the changes in the 
white matter are less severe than those in patients with cerebrovascular disease  [18] . Leuko-
araiosis in the healthy population is less intense and less frequent than in patients with dementia 
 [19] ; it is usually detected in 21% by CT and in 100% of those who are evaluated with MRI. 
Leukoaraiosis is therefore a finding of heterogeneous neuroimaging that may be associated with 
various clinical and pathological situations with a range of very wide prevalence, since there is 
not yet a clear consensus in the scientific community for its correct identification. To date, there 
is evidence of a significant relationship between leukoaraiosis and impaired cognitive functions 
(language, attention, memory, etc.)  [18] , but there are few studies linking leukoaraiosis and 
dementia. Moreover, other important processes in the lives of patients such as psycho-emotional 
and/or psychiatric processes are also altered in dementia  [20] . Of the possible emotional 
affective disorders that can present with dementia, the most prevalent is apathy.
 The term apathy is frequently used in the neuropsychiatric literature, but it is not included 
as a separate term in the current nosological classifications such as the DSM-IV  [21] and 
ICD-10  [22] . Apathy can be defined as a persistent deficit of motivation, a lack or decrease in 
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feelings, emotions, or interests that give rise to a significant reduction in self-generated goal-
directed behavior  [23, 24] . Apathy can be diagnosed with several standardized scales. 
However, they are not unified so that the percentage of AD patients suffering from apathy 
varies markedly between 19 and 76%  [25, 26] . However, apathy is the most frequent symptom 
in neuropsychiatric AD  [27, 28] and other dementias, and is associated with increased 
cognitive and functional impairment and a high burden on the caregiver  [29, 30] . There is also 
a growing body of evidence that apathy is a prominent feature of predementia states  [31–33] . 
In fact, there are indications that apathy could be a predictor of progression to dementia  [34] 
to the point that the severity of apathy would be closely related to cognitive function  [35] . 
Robert et al.  [36] evaluated patients meeting the criteria of amnestic MCI using the Apathy 
Inventory (AI) and then checked whether AD had evolved after 1 year. The results showed 
that the cognitive function of patients with MCI who had apathy was higher than that of those 
in whom apathy was not present. However, given its high prevalence in dementia cases in 
almost all studies, a study from 2008 developed a set of several international associations to 
establish a consensus on the diagnostic criteria for apathy, mainly in AD cases  [33] .
 Following the new consensus on leukoaraiosis and apathy, especially in cases of dementia, 
this study was proposed with the intent of establishing the prevalence and possible associ-
ation of leukoaraiosis and apathy in two clinical groups, one with MCI (prodromal state as 
possible AD) and another with AD institutionalized in seven residential centers in Spain. To 
our knowledge, it is the first study of its kind serving the two above factors (leukoaraiosis and 
apathy) conducted in Spain, using the new diagnostic criteria for apathy.
 Methods 
 The present work is a cross-sectional, descriptive, multicenter study. The sample consisted 
of 109 patients diagnosed with probable AD and 59 diagnosed with MCI according to the latest 
criteria of the NINCDS-ADRDA  [5, 6] published at the time of data collection by the relevant 
departments of neurology. All patients were residents in seven senior centers (belonging to 
the same foundation) located in seven cities in Spain, were aged 65 years or older and of both 
sexes. The subjects with AD at evolutionary stages 5 and 6 of the Global Deterioration Scale 
and Functional Assessment Staging (GDS and FAST, respectively) and MCI were selected, and 
all were diagnosed or reviewed by a neurologist within 6 months prior to the study. Reasons 
for exclusion were present sensory deficits that would prevent them from responding to tests, 
being diagnosed with depression by a psychiatrist (diagnosed by the Cornell Scale for 
Depression in Dementia  [37] ), and/or taking antidepressant treatment. Sociodemographic 
variables of age, sex, years of schooling, most prevalent chronic diseases, and scores on the 
following instruments were collected: (i) for the evaluation of apathy, the NPI-apathy  [38] 
subscale was used. It is one of the most widely used scales and follows the consensus criteria 
established in 2008  [33] . It is part of a larger questionnaire, the Neuropsychiatric Inventory 
(NPI), which to date has proven to be the most valid and reliable assessment of neuropsychi-
atric symptoms in subjects with dementia. It was initially developed by Cummings et al.  [39] 
to evaluate and quantify neurobehavioral disturbances in patients with dementia and to 
quantify the overhead caused by the caregiver situation. The score ranges from 0 to 12, with 
higher scores revealing more severe apathy, and sets the cutoff at 4. For this study, a Spanish 
adaptation of the NPI scale  [40] was used. (ii) For the diagnosis of leukoaraiosis, MRIs were 
performed with sounding devices of the same type (both hospitals gave their consent to the 
evaluation of the images for the study, as did the private schools where the tests were 
performed). The results were interpreted by two blinded neuroradiologists as to diagnosis of 
the patient and the study itself. They followed the directions on the Fazekas scale  [41] , which 
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is one of the most frequently used scales. It is classified as grade 0, absence of injury; grade 1, 
the existence of focal lesions; grade 2, at the beginning of the confluence of injuries, and grade 
3, diffuse lesions comprising whole regions  [18] . (iii) The Barthel test was administered to 
assess dependence. (iv) The participants were submitted to the Mini-Mental State Exami-
nation test using the Wolf method (MEC) to assess cognitive status. Data collection was carried 
out during 2012 and 2013. The sociodemographic variables were taken from the medical 
records and the apathy scale. The Barthel test and MEC were collected by the same researcher 
in collaboration with the medical and nursing staff of the respective residences. Leukoaraiosis 
diagnosis was made by two neuroradiologists within ±3 months after the collection of the data. 
Consent was obtained from the general management of the foundation, the residential centers, 
the ethics committee of the main residential center (in Madrid), and from all patients and/or 
guardians who were properly informed. The statistical treatment of the data was performed 
with SPSS 19.0 software. The researchers conducted a descriptive and a frequency analysis 
depending on each variable. The Kolmogorov-Smirnov (KS) test was used to examine normality, 
and the Levene test was used to evaluate the homogeneity of variances. If the criteria were met 
(normality and homoscedasticity), a parametric test was used: Student’s t test (for quanti-
tative variables) and the χ 2 test (for qualitative variables) to compare the two groups. Corre-
lation tests were also used to establish a possible link between quantitative (Pearson) and 
semiquantitative (Spearman) parameters, as appropriate (α = 0.05 in all cases).
 Results 
 Regarding sociodemographic variables and other collections, of the 109 subjects with 
AD, 74% were female, had a mean age of 82.3 years, 57.1% were at stage 5, and 42.9% were 
at stage 6 GDS. Regarding the 59 patients with MCI, 64.3% were women, had a mean age of 
77.8 years, and 67.8% were amnestic MCI. The KS test indicated normality (KS = 0.083, p = 
0.200), and Levene homoscedasticity (17.27, p = 0.190) was also indicated. Parametric tests 
were conducted to evaluate the potential significant differences between the groups. The 
researchers conducted a MANOVA analysis to analyze the presence of possible differences in 
the scores of all parameters depending on the residence center and found no significant 






Age, years 77.8 (5.47) 82.3 (5.66) 0.124
Female, % 66 73 0.09














MEC 28.05 (0.9 3) 19.6 (2.17) 0.01
Barthel 75 (0.90) 55 (1.63) 0.00
 Values are represented as mean (SD), unless otherwise indicated.
 The p values were determined either by Student’s t (quantitative 
variables) or the χ2 (qualitative variables) tests; p < 0.05.
 Table 1.  Averages and 
percentages of sociodemographic 
variables and other tests
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 Table 1 shows the distribution of the groups by sociodemographic variables, background, 
Barthel scores, and MEC, along with the statistical significance tests performed (Student’s t 
test for quantitative variables and the χ 2 test for qualitative variables). It was found that there 
were no significant differences between the groups for age, sex, years of schooling as well as 
for diabetes and hyperlipidemia. There were significant differences in hypertension, MEC, 
and Barthel scores, resulting in the AD group being dependent on assistance and exhibiting a 
greater degree of cognitive impairment.
 Regarding the presence of leukoaraiosis and apathy, the results for both groups are 
presented in  figure 1 and  table 2 . They are coded in the presence/absence of diagnosis, with 
the significance test revealing significant differences between the groups, with greater 
presence of both apathy and leukoaraiosis in the older group with AD.
 On the other hand, in relation to chronic diseases present, as can be seen in  figure 2 , 
patients with both MCI and AD who had hypertension were those with the higher percentages 
of leukoaraiosis (67%) compared to other diseases such as dyslipidemia (31% with leuko-
araiosis) and diabetes (28%). Upon performing a test for statistical significance between 
those with and those without leukoaraiosis (n = 168), statistically significant differences were 







AD Fig. 1. Percentages of leukoarai-
osis and apathy in both groups. 
MCI AD p
Leukoaraiosis 46.8% 67.9% 0.00
Apathy 37.6% 71.4% 0.00
The p values were determined by the χ2 test. p < 0.05.
 Table 2. Percentages of 













 Fig. 2. Percentages of chronic dis-
ease in patients with leukoarai-
osis. 
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 Moreover, a correlation study between the different parameters was carried out. The 
existence of a positive correlation between age and leukoaraiosis (rs = 0.567, p = 0.00) but 
not between age and apathy (rs = 0.236, p = 0.085) was observed. A correlation between 
apathy and leukoaraiosis (rs = 0.478, p = 0.01) was also found. In addition, the results of the 
correlation between the stage of EA and apathy were significant (rs = 0.568, p = 0.00), as were 
those between AD and the stage of leukoaraiosis (rs = 0.654, p = 0.00). Regarding the presence 
of leukoaraiosis and MEC (rs = 0.685, p < 0.05), a negative correlation between apathy and 
MEC (rs = 0.425, p < 0.05) was also found.
 Discussion 
 The aim of this work was to study the prevalence of and possible relationship between 
apathy and leukoaraiosis in two groups of patients with different degrees of cognitive 
impairment (MCI and AD). Apathy is the most prevalent neuropsychiatric symptom in 
dementia, and leukoaraiosis is a frequent finding in cases of cognitive impairment. Our results 
showed a high prevalence of leukoaraiosis and apathy in AD patients and to a lesser but still 
significant extent in patients with MCI. Apathy and leukoaraiosis negatively correlated with 
patients’ scores using MEC, indicating greater cognitive apathy and increased presence of 
leukoaraiosis impairment in these patients. Leukoaraiosis showed a positive correlation with 
age, occurring to a greater degree in older patients. Furthermore, a significant relationship 
was found between the presence of apathy and leukoaraiosis in both MCI and AD, a finding 
that has been little studied  [20] and that may open new avenues of research linking the 
presence of both as a prognostic factor for the evolution and severity of dementia. We also 
found a statistical significance between the presence of leukoaraiosis and hypertension in 
patients, a finding supported by the literature, with various research linking leukoaraiosis 
with cardiovascular disease  [12, 14, 19] as leukoaraiosis is associated with a reduction in 
blood perfusion in areas where it appears  [42] . These results are consistent with the findings 
of other studies that found a high prevalence of apathy and leukoaraiosis in patients with 
dementia. Examples are the recent work by Mulin et al.  [43] who found apathy in 55% of the 
patients with AD as well as the one by Starkstein et al.  [26] who suggested that apathy in AD 
is a marker of evolution characterized by a more rapid progression of cognitive, functional, 
and emotional impairment compared to patients without apathy. This would be an issue for 
future research, to assess whether patients presenting with MCI progress to AD apathy as 
well as for how long and how severe, to propose possible regression studies. As for the strong 
presence of leukoaraiosis and its association with impaired cognitive function, these results 
are consistent with other research that indicates a positive significant relationship with 
cognitive impairment: a greater presence of leukoaraiosis leads to a greater cognitive dete-
rioration  [14, 18, 44, 45] . We also found a significant relationship between age and leukoara-
iosis, especially in older patients who have a higher prevalence of leukoaraiosis, as confirmed 
in previous studies  [16–20, 46] . In the case of the MCI group that is currently treated as 
prodromal AD and in which the concept of Dubois’ ADProd  [47] is used, it seems clear that 
the significant presence of apathy and leukoaraiosis should be assessed and investigated in 
more detail within the framework predictors that indicate progression to AD  [46] with all the 
remarkable consequences of an early screening and deterioration approach  [48] . Our recent 
study has used consensus criteria established in the scientific literature regarding apathy. 
Although a consensus also needs to be established for leukoaraiosis, our results are consistent: 
there is a clear relationship between these symptoms and the presence of dementia, both 
increasing as the disease progresses. In addition to age and the presence of hypertension as 
factors confirming the presence of leukoaraiosis, the study was a very interesting method of 
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research, especially in cases of vascular dementia and frontotemporal dementia  [19, 49] . As 
far as we know, few studies have jointly analyzed the presence of apathy and leukoaraiosis. 
The presence of both in AD patients is reported in the literature, but the heterogeneity of 
results is a clear indication of the need to continue reaching consensus diagnostic criteria. In 
conclusion, the presence of apathy and leukoaraiosis is associated with cognitive impairment 
and may prove to be a predictor of future dementia through the study of populations with 
MCI. The growing aging population, which is associated with a higher prevalence of leuko-
araiosis and chronic diseases such as hypertension, coupled with advances in neuroimaging 
techniques and the establishment of new criteria for detecting apathy establishes a scenario 
that advocates the early detection of dementia to establish preventive treatments that halt its 
advance in the general population.
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